Acinetobacter baumannii can cause a serious infection in solid-organ transplant (SOT) recipients, and more data on A. baumannii infection is needed. We sought to investigate the epidemiology and distribution of A. baumannii isolates in SOT recipients. We also investigated the risk factors for overall in-hospital mortality and infection-related 30-day mortality using multivariate logistic regression analysis. A double-center retrospective study of SOT recipients who were infected with A. baumannii between January 2003 and January 2015 was conducted. A total of 71 individuals developed 93 episodes of A. baumannii infection, with a mean age of 44.5 years (44.5±11.9 years). Ninety percent of recipients had nosocomial origin A. baumannii infection, with the bloodstream as the most common site of infection (32.4%). Septic shock developed in 23.9% (17 of 71) of all recipients with A. baumannii infection. Morbidity and mortality rates of A. baumannii infections were high in SOT recipients. The incidence rate of A. baumannii infection in SOT recipients was 3.9% (71 of 1,821). Overall in-hospital mortality and infection-related 30-day mortality were 53.5% (38 of 71) and 40.8% (29 of 71), respectively. Risk factors independently associated with overall in-hospital mortality were mechanical ventilation at onset of A. baumannii infection (odds ratio [OR] (OR 189.98,728.81; P,0.001) were identified as independent risk factors for infection-related 30-day mortality. In conclusion, the morbidity and mortality rates of A. baumannii infections were high in SOT recipients. Mechanical ventilation at onset of A. baumannii infection was associated with higher overall in-hospital mortality and infection-related mortality. For overall in-hospital mortality, liver or liver-kidney transplantation and late-onset A. baumannii infection, and for infection-related mortality, thrombocytopenia were also risk factors, respectively.
Background
Bacteria can cause serious infection after solid-organ transplantation (SOT), with significant morbidity and mortality rates. [1] [2] [3] [4] The overall infection rate of Acinetobacter baumannii infection among SOT recipients is 1.4%-6.1%, and the mortality rate ranges from 39% to 80%. [5] [6] [7] [8] [9] [10] A. baumannii is a non-lactose-fermenting Gram-negative bacilli widely distributed in nature. It is an increasingly resilient opportunistic pathogen in critically ill or immunocompromised patients, associated with soft-tissue infection, catheter-associated bacteremia, ventilator-associated pneumonia, urinary tract infection, and peritonitis.
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A. baumannii is particularly problematic, due to its capacity of persisting in the hospital environment, including among health care workers, resulting in clonal outbreaks. [14] [15] [16] [17] Although SOT recipients are particularly susceptible to A. baumannii infection with high morbidity and mortality, little has been published regarding the impact and features of A. baumannii infections. 5, 6, 8, 12, 18 Herein, in the largest samplesize cohort study specifically focusing on A. baumannii infections in SOT recipients so far, our objective was to determine the epidemiology and risk factors for mortality.
Materials and methods ethics statement
The study protocol was approved by the Third Xiangya Hospital, Central South University and the Zhongnan Hospital, Wuhan University Medical Ethical Committee prior to patient identification and data collection.
study population
This study was conducted at both the Third Xiangya Hospital, an 1,800-bed teaching hospital, affiliated with Central South University, Changsha, People's Republic of China (PRC), with an active abdominal SOT program (annual average of 30 liver and 150 kidney transplants) and Zhongnan Hospital, a 1,200-bed teaching hospital, affiliated with Wuhan University, Wuhan, PRC, with an active abdominal SOT program (annual average of 40 liver and 100 kidney transplants). The medical records of SOT recipients with symptomatic A. baumannii infection occurring between January 1, 2003 and January 1, 2015 at both hospitals were retrospectively reviewed. Maintenance immunosuppression was based on calcineurin inhibitors (cyclosporine or tacrolimus) and corticosteroids, with or without mycophenolate mofetil/ azathioprine.
study design and data collection
We performed a retrospective study to investigate the epidemiology of pathogens and risk factors for overall in-hospital mortality and infection-related 30-day mortality in SOT recipients with A. baumannii infection. Demographic and clinical characteristics included age, sex, induction immunosuppressives, body temperature at the onset of infection, site and date of diagnosis of A. baumannii infection, nosocomial origin of infection, empirical antimicrobial therapy, acute rejection, reoperation, multidrug-resistant (MDR) A. baumannii, intensive care unit (ICU) stay, mechanical ventilation, and septic shock, and the laboratory records of these recipients were analyzed. The laboratory variables were collected within the first 24 hours after the culture was drawn, including serum creatinine and albumin levels and white blood cell, platelet, and lymphocyte counts. All episodes of A. baumannii infection were reviewed, and only the first episode was included for further statistical analyses. The follow-up time of all recipients was at least 1 month after the onset of A. baumannii infection.
Definitions
The presence of infection, including bacteremia, pneumonia, peritonitis, pleuritis, vascular catheter and urinary tract infection, was defined based on the criteria suggested by the US Centers for Disease Control and Prevention. 19 Appropriate antimicrobial therapy was defined as use of a drug to which the isolated pathogen was susceptible in vitro within 48 hours of sampling for culture. 20 Infection was considered to be nosocomially acquired in patients who had been hospitalized for 48 hours or longer. Infection was categorized as early onset if it occurred 2 months (60 days) or less after SOT, or late onset if it occurred .2 months after SOT. 21 MDR A. baumannii was defined as acquired nonsusceptibility to at least one agent in three or more antimicrobial categories, which included aminoglycosides, carbapenems, extended-spectrum cephalosporins, fluoroquinolones, antipseudomonal penicillins + β-lactamase inhibitors, ampicillin-sulbactam, trimethoprimsulfamethoxazole, tetracyclines, and polymyxins. 22 Septic shock was diagnosed in recipients who had a positive culture and developed persistent dysfunction of at least one organ caused by hypoperfusion that was unresponsive to intravenous fluid challenge and unexplained by other causes. 23 Mortality was regarded as related to infection when death was associated with clinical signs of active A. baumannii infection without evidence of any other cause. 24 
statistical analysis
Continuous variables are expressed as medians ± standard deviation. The χ 2 and Fisher exact tests were used to analyze categorical variables. Overall in-hospital mortality rates and infection-related 30-day mortality rates were calculated, respectively. Univariate analysis was applied to examine the association between demographic/clinical variables and overall in-hospital/infection-related mortality. We included variables identified (P,0.10) by univariate analyses. Odds ratios (ORs) with 95% confidence interval (CIs) were calculated. Statistical analyses were performed using SPSS for Windows, version 22.0 (IBM Corporation, Armonk, NY, USA). Statistical significance was defined as P,0.05 (two-tailed). 
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Results
During the 12-year study period, 1,502 SOT recipients -1,305 kidney, 189 liver, three heart, four simultaneous liver-kidney, and one simultaneous kidney-pancreas recipients -in the Third Xiangya Hospital and 319 SOT recipients -239 kidney, 78 liver, and two simultaneous liver-kidney recipients -in Zhongnan Hospital were enrolled.
A total of 93 episodes of A. baumannii infection occurred in 71 SOT recipients: 48 were kidney-transplant recipients (67.6%), 21 liver recipients (29.6%), and two simultaneous liver-kidney recipients (2.8%) ( Table 1 ). The incidence rate of A. baumannii infection in SOT recipients was 3.9% (71 of 1,821), with the rate of 3.1% in kidney recipients and 8.4% in liver or simultaneous liver-kidney recipients. High-dose steroids ($750 mg) were used in eight (11.3%) recipients for acute rejection before A. baumannii infection. Tacrolimus and cyclosporine A were used in 62 (87.3%) and eight (11.3%) recipients, respectively. The remaining patient did not use any calcineurin inhibitors between liver transplantation and the onset of A. baumannii infection, due to a severe clinical condition. Among these 93 episodes of A. baumannii infection, the presumed sources of infection were the bloodstream (n=35, 37.6%), lung (n=33, 35.5%), urinary tract (n=16, 17.2%), intra-abdomen/biliary tract (n=6, 6.5%), thoracic cavity (n=2, 2.2%), and catheter (n=1, 1.1%). The median time to onset of A. baumannii infection after SOT transplantation was 38 days (interquartile range 8-111 days), and 61.3% (57 of 93) occurred as early onset.
The mean age for SOT recipients with A. baumannii infections was 44.5 years (44.5±11.9 years), among which 53 (74.6%) were male. Ninety percent of recipients had nosocomial origin A. baumannii infection. Seventeen patients (23.9%) had a body temperature of 39°C or higher at the onset of A. baumannii infection. The most common cases were recipients with A. baumannii bacteremias (23 
Discussion
Invasive bacterial infections have become a leading contributor to patient morbidity and mortality among SOT recipients. 25 A. baumannii is an increasing problem among SOT recipients. Not only is A. baumannii environmentally resilient but this pathogen can also readily develop antibiotic resistance. van Delden et al reported that the prevalence of MDR Acinetobacter is increasing, and is related to higher rates of treatment failure in SOT recipients. 26 The incidence rate of A. baumannii infection in SOT recipients was 3.9% (71 of 1,821), with rates of 3.1% in kidney recipients and 8.4% in liver or simultaneous liver-kidney recipients, in our present study. Although in more transplant centers, including ours, higher-immunosuppression regimens are used in kidneytransplant recipients, the incidence rate of A. baumannii 
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A. baumannii in solid-organ transplantation infection in liver or simultaneous liver-kidney recipients was higher than that in kidney recipients, because patients undergoing liver or simultaneous liver-kidney transplantation had several conditions that favor postoperative A. baumannii infection, such as preoperative malnutrition due to end-stage liver disease, insulin resistance, major surgical trauma, massive intraoperative bleeding and transfusions, the placement of various catheters, and long duration of antibiotic use before and after transplantation, which could enhance the likelihood of emergence of A. baumannii. Ninety percent of recipients had A. baumannii infection with nosocomial origin in our present study, in alignment with previous studies 5, 15 reporting A. baumannii to be almost exclusively a nosocomial pathogen. We found that 74.6% of recipients developed MDR A. baumannii infection, and the incidence rate of MDR A. baumannii was higher than that of MDR A. baumannii reported by Kusne et al (64%). 4 The possible reasons to explain this included MDR being defined as resistance to three or more major classes of antibiotics historically effective against A. baumannii (fluoroquinolones, carbapenems, aminoglycosides, penicillins, and cephalosporins) in the study conducted by Kusne et al whereas in our present study, MDR was defined as acquired nonsusceptibility to at least one agent in three or more antimicrobial categories, which included nine classes of antibiotics.
Our present study showed that A. baumannii infection was associated with high morbidity (3.9%), as well as high overall in-hospital mortality (53.5%) and infection-related 30-day mortality (40.8%), in line with previous studies that reported an incidence rate of up to 6.1% and an extremely high mortality rate of up to 80% among SOT recipients with A. baumannii infection. [5] [6] [7] [8] [9] [10] Mechanical ventilation associated with both overall inhospital mortality and infection-related 30-day mortality were in agreement with a recent study claiming that the risk of A. baumannii infection-associated mortality was higher in SOT patients on mechanical ventilation. 7 Mechanical ventilation support is associated with both overall in-hospital mortality and infection-related 30-day mortality because it probably surrogates markers of clinical severity. 7 We also found that late-onset A. baumannii infection was an associated risk factor with overall in-hospital mortality. The association partly reflects the effect of clinical severity on outcomes, given SOT recipients with lateonset A. baumannii infection needed more frequent ICU stay (80% vs 66%) and ventilator dependence (70% vs 24%) when compared with recipients with early onset infection. We revealed that liver or liver-kidney transplantation was significantly related to overall mortality, in accordance with Moreno et al who found liver transplantation to be a risk factor for higher mortality in transplant recipients with bloodstream infections. 27 We also revealed that thrombocytopenia was a risk factor associated with infection-related mortality. This finding probably reflects a confounding factor, as thrombocytopenia developed more frequently among liver recipients who presented with higher baseline clinical severity. Our findings consolidated results from previous studies of SOT recipients, which reported that lower platelet count to be associated with infection-related mortality. 24, 28, 29 To the best of our knowledge, this is the largest study specifically focusing on A. baumannii infections to investigate the epidemiology, distribution, and risk factors for overall in-hospital and infection-related 30-day mortality in SOT recipients. However, the present study has certain limitations. Firstly, our study was a small retrospective chart review with potential limitations, such as data limited to existing medical records. Secondly, for the relatively small number of cases and deaths, the statistical power may be insufficient. Thirdly, we may have underestimated the true rates of A. baumannii infections in SOT recipients, given that 1) cases of A. baumannii infections outside our institution were not identified, and 2) some cases received empiric courses of antimicrobial therapy before specimens for bacterial culture were obtained. Finally, though we tried to include all relevant data, other unidentified variables are probably risk factors for mortality. The strength of our study is the long study period covering two centers in two different cities in the PRC. However, given the retrospective data collection and risk for bias, all reported findings should be interpreted with care.
Conclusion and recommendation
High morbidity and high unfavorable outcomes in SOT recipients with infections due to A. baumannii were observed. This study confirmed that the risk factors significantly associated with increased mortality in SOT recipients with A. baumannii infection were mechanical ventilation, liver or liver-kidney transplantation, thrombocytopenia, and lateonset infection. Therefore, the clinical and laboratory factors noted in the present study could be useful for clinicians to identify SOT recipients with A. baumannii infection who are at high risk for mortality.
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